SYMBIOTEC

September 21, 2026

To,	To,
The Listing Department,	The Listing Department
BSE Limited,	National Stock Exchange of India Ltd.,
Phiroze Jeejeebhoy Towers,	Exchange Plaza, Bandra Kurla Complex,
Dalal Street, Mumbai – 400001	Bandra (East), Mumbai – 400051
Scrip code: 544889	**Symbol**: SYMBIOTEC

Sub.: Outcome of the Board Meeting of the Company.

Ref.: 1. Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations");
2. Our intimation dated September 11, 2026

Dear Sir / Madam,

With reference to the captioned subject, this is to inform you that the Board of Directors of the Company at its meeting held today i.e., Monday, September 21, 2026, have inter alia considered and approved the Unaudited Standalone & Consolidated Financial Results for the quarter ended June 30, 2026 ("unaudited Financial Results").

Enclosed are the Unaudited Financial Results along with Limited Review Reports for your records. (Pursuant to Regulation 47 of the SEBI Listing Regulations, extract of these results will be published in newspapers).

The meeting commenced at 03:30 p.m. and concluded at 04:45 p.m.

The Trading Window for dealing in Company's securities shall remain closed until 48 hours from this announcement.

The above information is being made available on website of the Company i.e. https://investor.symbiotec.com/performance?tab=quarterly

Thanking You.

Sincerely,
For **Symbiotec Pharmalab Limited**

SALIL JAIN
Digitally signed by SALIL JAIN
Date: 2026.09.21 18:23:52 +05'30'

Salil Jain
Company Secretary and Compliance Officer
Membership No. A41610

Encl: As above

S R B C & CO LLP
Chartered Accountants

12th Floor, The Ruby
29 Senapati Bapat Marg
Dadar (West)
Mumbai - 400 028, India

Tel : +91 22 6819 8000

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Symbiotec Pharmalab Limited (formerly known as Symbiotec Pharmalab Private Limited)

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Symbiotec Pharmalab Limited (formerly known as Symbiotec Pharmalab Private Limited) (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors . Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the financial results of the subsidiaries. For list of entities, refer to Annexure A below.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

S R B C & CO LLP MUMBAI CHARTERED ACCOUNTANTS

6. The accompanying Statement includes unaudited interim financial results and other financial information in respect of four subsidiaries, whose interim financial results and other financial information includes total revenues of Rs 8.48 million, total net loss after tax of Rs. 3.72 million and total comprehensive loss of Rs. 2.19 million, for the quarter ended June 30, 2026.

   The unaudited interim financial information/ financial results and other unaudited financial information of these subsidiaries have not been reviewed by any auditor and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, this interim financial results/financial information are not material to the Group.

   Our conclusion on the Statement in respect of matters stated in para 6 above is not modified with respect to the financial results/financial information certified by the Management.

7. The Ind AS financial information of the Group for the quarter ended March 31, 2026, included in these unaudited consolidated Ind AS financial results have not been subject to an audit or review and are the balancing figures between the audited figures in respect of full financial year ended Mach 31, 2026, and the figures (unaudited/unreviewed) upto the end of third quarter ended December 31, 2025.

For S R B C & CO LLP
Chartered Accountants
ICAI Firm registration number: 324982E/E300003

S R B C & CO LLP
MUMBAI
CHARTERED ACCOUNTANTS

per Anil Jobanputra
Partner
Membership No.: 110759

UDIN: 26110759MVFAZK6262

Place: Mumbai
Date: September 21, 2026

S R B C & CO LLP
Chartered Accountants

Annexure A

(Referred to in paragraph 4 of our report of even date)

List of entities included in these results

Sr. No.	Name of entity	Relationship
1	Symbiotec Pharamalab Limited (SPL)	Holding Company
2	Knovea Pharmaceuticals Private Limited (KPPL)	Subsidiary of SPL
3	Symbiotec Zenfold Private Limited (SZPL)	Subsidiary of SPL
4	Navisci Pte Limited (NPL)	Subsidiary of SPL
5	Xinjiang Symbiotec Biotechnology Limited (XSBL)	Subsidiary of SPL
6	Symbiotec Biologics Private Limited (SBPL)	Subsidiary of SPL
7	Xenamed Corp.	Subsidiary of NPL

S R B C & CO LLP
MUMBAI
CHARTERED ACCOUNTANTS

Symbiotec Pharmalab Limited

Corporate Identity Number (CIN):U24232MP2002PLC015293

Regd. Office:385/2, Pigdamber, Rau, Mhow,Indore – 453331, Madhya Pradesh, India

Email: investorrelations@symbiotec.com Website: https://symbiotec.com

Statement of unaudited consolidated financial results for the quarter ended June 30,2026

(Rs. in Million)

Particulars	Quarter ended			Year ended
	June 30,2026 (Unaudited)	March 31,2026 (Refer Note 3)	June 30,2025 (Audited)	March 31,2026 (Audited)
Income				
Revenue from operations	2,181.50	2,452.54	2,031.72	8,691.49
Other income	3.38	1.58	26.41	31.09
Total income (A)	**2,184.88**	**2,454.12**	**2,058.13**	**8,722.58**
Expenses				
Cost of raw materials, packing material and consumables consumed	755.59	911.19	773.27	3,154.64
Employee benefit expenses	464.21	423.29	351.41	1,543.39
Finance costs	61.79	72.55	52.77	253.27
Depreciation and amortisation expense	218.24	197.53	105.08	532.83
Other expenses	509.73	497.10	327.38	1,614.89
Total expenses (B)	**2,009.56**	**2,101.66**	**1,609.91**	**7,099.02**
Profit before exceptional item and tax (C= (A-B))	**175.32**	**352.46**	**448.22**	**1,623.56**
Exceptional item (D)				
Impact of New wages code on Gratuity and Leave encashment	-	-	-	89.93
Profit before tax (E=(C-D))	**175.32**	**352.46**	**448.22**	**1,633.63**
Income Tax expense				
Current tax charge Charge/(Credit)	160.20	129.26	160.11	593.75
Adjustment of tax relating to earlier period/year Charge/(Credit)	-	1.96	-	1.96
Deferred Tax Charge/(Credit)	(125.49)	(54.08)	(11.09)	(140.04)
Deferred Tax relating to Exceptional items Charge/(Credit)	-	-	-	(21.07)
Total Income tax expense/(credit) (F)	**34.71**	**77.14**	**149.02**	**434.60**
Net Profit for the period/year (G= (E-F))	**140.61**	**275.32**	**299.20**	**1,099.03**
Other comprehensive income, net of income tax				
Items that will be reclassified to profit and loss in subsequent period				
Exchange difference on translation of foreign operations	1.53	(8.76)	0.48	(8.10)
Items that will not be reclassified to profit and loss in subsequent period				
Re-measurements gains/ (losses) on defined benefit plans	(1.11)	(1.75)	(2.05)	(3.72)
Income tax effect on above	0.24	0.17	0.49	0.66
Total (H)	(0.87)	(1.58)	(1.56)	(3.06)
Total other comprehensive income/(loss), net of income tax (I)	**0.66**	**(10.34)**	**(1.08)**	**(11.16)**
Total comprehensive income for the period/year (J)=(G+I)	**141.27**	**264.98**	**298.12**	**1,087.87**
Total comprehensive income for the period/year attributable to:				
Owners of the Parent Company	141.21	264.53	298.08	1,087.38
Non-controlling interests	0.06	0.45	0.04	0.49
Net Profit attributable to:				
Owners of the Parent Company	140.56	275.13	299.18	1,098.82
Non-controlling interests	0.05	0.19	0.02	0.21
Other comprehensive income/(loss) attributable to:				
Owners of the Parent Company	0.65	(10.60)	(1.10)	(11.44)
Non-controlling interests	0.01	0.26	0.02	0.28
Paid-up equity share capital (Face value of Rs 2/- per share)	62,734,851	62,734,851	54,681,980	62,734,851
Other Equity				11,371.83
Earnings per share (of face value Rs. 2/- per share) [not annualised]				
Basic (in Rs.)	2.24	4.78	5.37	19.10
Diluted (in Rs.)	2.24	4.76	5.34	19.00

Symbiotec Pharmalab Limited INDIA

SIGNED FOR IDENTIFICATION BY

S R B C & CO LLP MUMBAI

Symbiotec Pharmalab Limited

Corporate Identity Number (CIN):U24232MP2002PLC015293

Regd. Office:385/2, Pigdamber, Rau, Mhow,Indore – 453331, Madhya Pradesh, India

Email: investorrelations@symbiotec.com Website: https://symbiotec.com

Statement of unaudited consolidated financial results for the quarter ended June 30,2026

Notes:

1. The Unaudited Consolidated Financial Results ("Statement") of the Symbiotec Pharmalab Limited ("Holding Company") and its subsidiaries (together referred to as the 'Group') for the quarterended on June 30, 2026, has been reviewed by the Audit Committee and thereafterapproved by the Board of Directorsat its meeting held on September 21, 2026. The statutory auditors have carried out a limited review of these Statement and issued unmodified report thereon.

2. This Statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, (Ind AS 34) Interim Financial Reporting prescribed under section 133 of Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

3. The figures for the quarter ended March 31, 2026, have not been audited or reviewed by statutory auditors. The said figures for the quarter ended March 31, 2026, included in these Statement are the balancing figures between the audited figures in respect of full financial year ended March 31, 2026, and the figures (unaudited/unreviewed) up to the end of the third quarter ended December 31, 2025. However, the management has exercised necessary due diligence to ensure that the said figures for the quarter ended March 31, 2026, provide a true and fair view of the Group's affairs.

4. Subsequent to the quarter ended June 30, 2026, the Holding Company has completed its Initial Public Offering ("IPO") of 1,77,86,442 nos. of equity shares of face value of Rs. 2 each at an issue price of Rs. 988 per share (including a share premium of Rs. 986 per share). A discount of Rs. 90 was offered to eligible employees bidding in the employee's reservation portion of 33,407 nos. of equity shares. The issue comprised of 15,21,261 nos. of equity shares offered as fresh issue aggregating to Rs. 1,500.00 million and 1,62,65,181 nos. of equity shares offered as offer for sale by selling shareholders aggregating to Rs. 16,070.00 million. The Holding Company will provide an update on the utilisation of IPO proceeds towards the objects of the fresh issue effective next reporting period based on actual utilisation of funds. Pursuant to IPO, the equity shares of the Holding Company were listed on National Stock Exchange of India Limited ("NSE") and BSE Limited ("BSE") on September 1, 2026.
Pursuant to Initial Public Offering ("IPO"), the Statement of Group for the quarter ended June 30, 2026, is drawn up for the first time in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

5. The Group is primarily engaged in the business of manufacturing and selling of Pharmaceutical products, including Active Pharmaceuticals Ingredients (API) and Intermediates. Accordingly, there is no separate reportable segment as per Ind AS 108 on 'Operating Segment'.

6. Exceptional item includes:

Particulars	Quarter ended			Year ended
	June 30,2026 (Unaudited)	March 31,2026 (Refer Note 3)	June 30,2025 (Audited)	March 31,2026 (Audited)
Impact of new wage code on gratuity and leave encashment	-	-	-	89.93

7. These consolidated financial results of the Group for the quarter ended June 30 2026 are available on the BSE Limited website (URL: www.bseindia.com), National Stock Exchange of India Limited (URL: www.nseindia.com), and on the Company's website (URL: www.symbiotec.com).

For and on behalf of the Board of Directors of
Symbiotec Pharmalab Limited
CIN : U24232MP2002PLC015293

ANIL SATWANI Digitally signed by ANIL SATWANI Date: 2026.09.21 16:47:21 +05'30'

Anil Satwani
Managing Director
Place: Indore
Date: September 21,2026

SIGNED FOR IDENTIFICATION BY

S R B C & CO LLP
MUMBAI

Symbiotec Pharmalab Limited INDIA

S R B C & CO LLP
Chartered Accountants

12th Floor, The Ruby
29 Senapati Bapat Marg
Dadar (West)
Mumbai - 400 028, India

Tel : +91 22 6819 8000

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Symbiotec Pharmalab Limited (formerly known as Symbiotec Pharmalab Private Limited)

1. We have reviewed the accompanying statement of unaudited standalone financial results of Symbiotec Pharmalab Limited (formerly known as Symbiotec Pharmalab Private Limited) (the "Company") for the quarter ended June 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

S R B C & CO LLP
MUMBAI
CHARTERED ACCOUNTANTS

5. The Ind AS financial information of the Company for the quarter ended March 31, 2026, included in these unaudited standalone Ind AS financial results have not been subject to an audit or review and are the balancing figures between the audited figures in respect of full financial year ended Mach 31, 2026, and the figures (unaudited/unreviewed) upto the end of third quarter ended December 31, 2025.

For S R B C & CO LLP
Chartered Accountants
ICAI Firm registration number: 324982E/E300003

per Anil Jobanputra
Partner
Membership No.: 110759

UDIN: 26110759RHOXFZ2124

Place: Mumbai
Date: September 21, 2026

Symbiotec Pharmalab Limited
Corporate Identity Number (CIN):U24232MP2002PLC015293
Regd. Office:385/2, Pigdamber, Rau, Mhow,Indore – 453331, Madhya Pradesh, India
Email: investorrelations@symbiotec.com Website: https://symbiotec.com

Statement of unaudited standalone financial results for the quarter ended June 30,2026

(Rs. in Million)

Particulars	Quarter ended			Year ended
	June 30,2026 (Unaudited)	March 31,2026 (Refer Note 3)	June 30,2025 (Audited)	March 31,2026 (Audited)
Income				
Revenue from operations	2,108.43	2,130.76	2,042.62	8,451.65
Other income	195.47	186.75	114.74	567.25
Total income (A)	**2,303.90**	**2,317.51**	**2,157.36**	**9,018.90**
Expenses				
Cost of raw materials, packing material and consumables consumed	783.97	904.37	773.98	3,193.79
Employee benefit expenses	352.20	353.07	339.19	1,422.37
Finance costs	56.20	64.48	51.14	238.00
Depreciation and amortisation expense	101.47	113.10	92.99	393.66
Other expenses	379.86	383.95	305.99	1,429.21
Total expenses (B)	**1,873.70**	**1,818.97**	**1,563.29**	**6,677.03**
Profit before exceptional items and tax (C= (A-B))	**630.20**	**498.54**	**594.07**	**2,341.87**
Exceptional Items :				
Provision for impairment	-	528.13	-	528.13
Impact of New wages code on Gratuity and Leave encashment	-	-	-	83.21
Total (D)	**-**	**528.13**	**-**	**611.34**
Profit/(Loss) before tax (E=(C-D))	**630.20**	**(29.59)**	**594.07**	**1,730.53**
Income Tax expense				
Current tax charge Charge/(Credit)	160.20	129.26	160.11	593.75
Adjustment of tax relating to earlier period/year Charge/(Credit)	-	1.96		1.96
Deferred Tax Charge/(Credit)	(0.08)	(3.91)	(11.09)	(2.50)
Deferred Tax relating to Exceptional items Charge/(Credit)	-	-	-	(20.94)
Total Income tax expense/(credit) (F)	**160.12**	**127.31**	**149.02**	**572.27**
Net Profit/(Loss) for the period/year (G=(E-F))	**470.08**	**(156.90)**	**445.05**	**1,158.26**
Other comprehensive income, net of income tax				
Items that will not be reclassified to profit and loss in subsequent period				
Re-measurements gains/ (losses) on defined benefit plans	(0.66)	(0.66)	(1.94)	(2.62)
Income tax effect on above	0.17	0.17	0.49	0.66
Total other comprehensive income, net of income tax (H)	**(0.49)**	**(0.49)**	**(1.45)**	**(1.96)**
Total comprehensive income for the period/year (I)=(G+H)	**469.59**	**(157.39)**	**443.60**	**1,156.30**
Paid-up equity share capital (Face value of Rs 2/- per share)	62,734,851	62,734,851	54,681,980	62,734,851
Other Equity				12,418.11
Earnings per share (of face value Rs. 2/- per share) [not annualised]				
Basic (in Rs.)	7.49	(2.73)	8.00	20.13
Diluted (in Rs.)	7.49	(2.71)	7.95	20.03

Symbiotec Pharmalab Limited INDIA

SIGNED FOR IDENTIFICATION BY

S R B C & CO LLP
MUMBAI

Symbiotec Pharmalab Limited

Corporate Identity Number (CIN):U24232MP2002PLC015293

Regd. Office:385/2, Pigdamber, Rau, Mhow,Indore – 453331, Madhya Pradesh, India

Email: investorrelations@symbiotec.com Website: https://symbiotec.com

Statement of unaudited standalone financial results for the quarter ended June 30,2026

Notes:

1. The Unaudited Standalone Financial Results ("Statement") for the quarter ended on June 30, 2026, has been reviewed by the Audit Committee and thereafter approved by the Board of Directors of the Symbiotec Pharmalab Limited ("Company") at its meeting held on September 21,2026. The statutory auditors hava carried out a limited review of these Statement and issued unmodified report thereon.

2. This Statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, (Ind AS 34) Interim Financial Reporting prescribed under section 133 of Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

3. The figures for the quarter ended March 31, 2026, have not been audited or reviewed by statutory auditors. The said figures for the quarter ended March 31, 2026, included in these Statement are the balancing figures between the audited figures in respect of full financial year ended March 31, 2026, and the figures (unaudited/unreviewed) up to the end of the third quarter ended December 31, 2025. However, the management has exercised necessary dua diligence to ensure that the said figures for the quarter ended March 31, 2026, provide a true and fair view of the Company's affairs.

4. Subsequent to the quarter ended June 30, 2026, the Company has completed its IPO of 1,77,86,442 nos. of equity shares of face value of Rs. 2 each at an issue price of Rs. 988 per share (including a share premium of Rs. 986 per share). A discount of Rs. 90 was offered to eligible employees bidding in the employee's reservation portion of 33,407 nos. of equity shares. The issue comprised of 15,21,261 nos. of equity shares offered as fresh issue aggregating to Rs. 1,500.00 million and 1,62,65,181 nos. of equity shares offered as offer for sale by selling shareholders aggregating to Rs. 16,070.00 million. The Company will provide an update on the utilisation of IPO proceeds towards the objects of the fresh issue effective next reporting period based on actual utilisation of funds. Pursuant to IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited ("NSE") and BSE Limited ("BSE") on September 1, 2026.

Pursuant to Initial Public Offering ("IPO"), these Statement of the Company for the quarter ended June 30, 2026, is drawn up for the first time in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as emended.

5. The Company is primarily engaged in the business of manufacturing and selling of Pharmaceutical products, including Active Pharmaceuticals Ingredients (API) and Intermediates. Accordingly, there is no separate reportable segment as per Ind AS 108 on 'Operating Segment'.

6. Exceptional item includes:

Particulars	Quarter ended			Year ended
	June 30,2026 (Unaudited)	March 31,2026 (Refer Note 3)	June 30,2025 (Audited)	March 31,2026 (Audited)
Impact of new wage code on gratuity and leave encashment	-	-	-	83.21
Provision for Impairment of investment and loans in/given to subsidiary	-	528.13	-	528.13
Total	**-**	**528.13**	**-**	**611.34**

7. These standalone financial results of the Company for the quarter ended 30 June 2026 are available on the BSE Limited website (URL: www.bseindia.com), National Stock Exchange of India Limited (URL: www.nseindia.com), and on the Company's website (URL: www.symbiotec.com).

For and on behalf of the Board of Directors of
Symbiotec Pharmalab Limited
CIN : U24232MP2002PLC015293

ANIL SATWANI Digitally signed by ANIL SATWANI Date: 2026.09.21 16:48:54 +05'30'

Anil Satwani
Managing Director
Place: Indore
Date: September 21,2026

SIGNED FOR IDENTIFICATION BY
S R B C & CO LLP
MUMBAI

Symbiotec Pharmalab Limited INDIA